KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) Equity Average (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Equity Average for 16 consecutive years, with $7.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average rose 0.95% to $7.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $7.1 billion, a 0.95% increase, with the full-year FY2025 number at $7.0 billion, down 8.41% from a year prior.
  • Equity Average was $7.1 billion for Q4 2025 at Bio-Rad Laboratories, up from $6.9 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $14.5 billion in Q4 2021 to a low of $6.6 billion in Q1 2025.
  • A 5-year average of $9.1 billion and a median of $8.8 billion in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 70.12% in 2021, then plummeted 37.65% in 2022.
  • Bio-Rad Laboratories' Equity Average stood at $14.5 billion in 2021, then crashed by 37.65% to $9.0 billion in 2022, then dropped by 5.17% to $8.6 billion in 2023, then decreased by 18.07% to $7.0 billion in 2024, then rose by 0.95% to $7.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BIO's Equity Average are $7.1 billion (Q4 2025), $6.9 billion (Q3 2025), and $6.9 billion (Q2 2025).